[go: up one dir, main page]

NO20030787L - Opplösningssammensetning av et antibiotisk oksazolidinonlegemiddel med forhöyet legemiddelinnhold - Google Patents

Opplösningssammensetning av et antibiotisk oksazolidinonlegemiddel med forhöyet legemiddelinnhold

Info

Publication number
NO20030787L
NO20030787L NO20030787A NO20030787A NO20030787L NO 20030787 L NO20030787 L NO 20030787L NO 20030787 A NO20030787 A NO 20030787A NO 20030787 A NO20030787 A NO 20030787A NO 20030787 L NO20030787 L NO 20030787L
Authority
NO
Norway
Prior art keywords
drug
elevated
dissolution composition
content
antibiotic
Prior art date
Application number
NO20030787A
Other languages
English (en)
Other versions
NO20030787D0 (no
Inventor
Sandra M Sims
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of NO20030787D0 publication Critical patent/NO20030787D0/no
Publication of NO20030787L publication Critical patent/NO20030787L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medical Informatics (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20030787A 2000-08-22 2003-02-19 Opplösningssammensetning av et antibiotisk oksazolidinonlegemiddel med forhöyet legemiddelinnhold NO20030787L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22684600P 2000-08-22 2000-08-22
US28534701P 2001-04-20 2001-04-20
PCT/US2001/025932 WO2002015940A2 (en) 2000-08-22 2001-08-20 Solution of an oxazolidinone antibiotic drug

Publications (2)

Publication Number Publication Date
NO20030787D0 NO20030787D0 (no) 2003-02-19
NO20030787L true NO20030787L (no) 2003-04-03

Family

ID=26920930

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20030787A NO20030787L (no) 2000-08-22 2003-02-19 Opplösningssammensetning av et antibiotisk oksazolidinonlegemiddel med forhöyet legemiddelinnhold

Country Status (20)

Country Link
US (1) US6989381B2 (no)
EP (1) EP1311296B1 (no)
JP (1) JP2004506699A (no)
KR (1) KR20030027047A (no)
AR (1) AR030470A1 (no)
AT (1) ATE312627T1 (no)
AU (2) AU8508701A (no)
BR (1) BR0113363A (no)
CA (1) CA2419597A1 (no)
CY (1) CY1105464T1 (no)
DE (1) DE60115910T2 (no)
DK (1) DK1311296T3 (no)
ES (1) ES2250461T3 (no)
IL (1) IL154423A0 (no)
MX (1) MXPA03001531A (no)
NO (1) NO20030787L (no)
NZ (1) NZ524158A (no)
PE (1) PE20020300A1 (no)
PL (1) PL365674A1 (no)
WO (1) WO2002015940A2 (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9928568D0 (en) 1999-12-03 2000-02-02 Zeneca Ltd Chemical compounds
GB0009803D0 (en) 2000-04-25 2000-06-07 Astrazeneca Ab Chemical compounds
US6696426B2 (en) 2000-08-22 2004-02-24 Pharmacia Corporation Preservative free ophthalmic oxazolidinone antibiotic drug delivery systems
WO2004098592A1 (ja) * 2003-05-06 2004-11-18 Senju Pharmaceutical Co. Ltd. オキサゾリジノン誘導体含有組成物
DE10355461A1 (de) 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
NZ599151A (en) * 2009-10-13 2014-07-25 Melinta Therapeutics Inc Pharmaceutical composition comprising radezolid or salt thereof and uses thereof
WO2015042170A1 (en) 2013-09-17 2015-03-26 Wayne State University Compositions and uses of combinations of dim-related indoles and selected anti-androgen compounds
WO2018055581A1 (en) * 2016-09-24 2018-03-29 Jodas Expoim Private Limited Stable injectable composition of oxazolidinone
US10870646B2 (en) * 2017-02-27 2020-12-22 University Of St. Thomas Oxazolidinones and pharmaceutical compositions thereof for treating bacterial infections, including infection of Mycobacterium tuberculosis
CN108571074A (zh) * 2018-05-25 2018-09-25 夏念涛 一种装配式钢结构矩形组合柱框架体系及其装配方法
WO2021184339A1 (en) 2020-03-20 2021-09-23 Merck Sharp & Dohme Corp. Oxazolidinone compound and methods of use thereof as an antibacterial agent

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU190818B (en) 1982-11-09 1986-11-28 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu Process for producing complexes of piperonyl-butoxide-cyclodextrin
HU194858B (en) 1982-12-03 1988-03-28 Chinoin Gyogyszer Es Vegyeszet Process for producing dibenzo/b,d/pirane derivatives and pharmaceutical compositions containing them
DE3346123A1 (de) 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US6407079B1 (en) 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
ZA892684B (en) 1988-04-27 1989-12-27 Warner Lambert Co Cyclodextrin complexes of 5-aminohexahydropyrimidine compounds
US5164510A (en) 1988-09-15 1992-11-17 The Upjohn Company 5'Indolinyl-5β-amidomethyloxazolidin-2-ones
US5231188A (en) 1989-11-17 1993-07-27 The Upjohn Company Tricyclic [6.5.51]-fused oxazolidinone antibacterial agents
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5124154A (en) 1990-06-12 1992-06-23 Insite Vision Incorporated Aminosteroids for ophthalmic use
EP0519428B1 (en) 1991-06-21 2000-09-20 Takeda Chemical Industries, Ltd. Cyclodextrin compositions with fumagillol derivates
CA2119556C (en) 1991-11-01 2004-07-06 Michael Robert Barbachyn Substituted aryl- and heteroaryl-phenyloxazolidinones
US5602112A (en) 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
US5324718A (en) 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
JP2879395B2 (ja) 1992-10-26 1999-04-05 富士写真フイルム株式会社 ロダシアニン化合物及びシクロデキストリンを含有する抗癌性組成物
ES2062941B1 (es) * 1993-03-15 1995-10-01 Uriach & Cia Sa J Nuevos derivados de azol activos por via oral.
US5688792A (en) * 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
CA2174107C (en) 1993-11-22 2005-04-12 Steven J. Brickner Esters of substituted-hydroxyacetyl piperazine phenyl oxazolidinones
BE1008307A3 (fr) 1994-06-16 1996-04-02 Europharmaceuticals Sa Sel de nimesulide hydrosoluble, solution aqueuse le contenant, sa preparation et son utilisation.
DE4425613A1 (de) 1994-07-20 1996-01-25 Bayer Ag 5-gliedrige Heteroaryl-oxazolidinone
DE4425612A1 (de) 1994-07-20 1996-04-04 Bayer Ag 6-gliedrige stickstoffhaltige Heteroaryl-oxazolidinone
US5807895A (en) 1994-11-29 1998-09-15 Schwarz Pharma, Inc. Use of prostaglandin E1, E2 or analogs to prevent renal failure induced by medical tests that utilize contrast media agents
ES2163004T3 (es) 1995-02-03 2002-01-16 Upjohn Co Feniloxazolidinona sustituida por un anillo heteroaromatico como agente antimicrobiano.
ZA962214B (en) 1995-04-10 1996-10-07 Farmarc Nederland Bv Pharmaceutical composition
AU5780696A (en) 1995-06-02 1996-12-18 Takeda Chemical Industries Ltd. Stabilized composition comprising an antiulcerative benzimid azole
US5824668A (en) 1996-11-07 1998-10-20 Supergen, Inc. Formulation for administration of steroid compounds
GB9601666D0 (en) 1996-01-27 1996-03-27 Zeneca Ltd Chemical compounds
HUP9600847A3 (en) 1996-04-02 1999-08-30 Human Oltoanyagtermeloe Es Gyo Nonstochiometric compds. of primycins with ciclodextrin derivatives, pharmaceutical compns. contg. the said compds. and process for preparing them
CZ298060B6 (cs) 1996-04-11 2007-06-06 Pharmacia & Upjohn Company Zpusob prípravy oxazolidinonu
SE9601556D0 (sv) 1996-04-24 1996-04-24 Astra Ab New pharmaceutical formulation of a thrombin inhibitor for parenteral use
ATE222103T1 (de) 1997-02-27 2002-08-15 Novo Nordisk As Inklusionskomplexe in waessriger loesung
US6046177A (en) 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US5874418A (en) 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
ES2210769T3 (es) 1997-06-13 2004-07-01 Cydex Inc. Compuesto con vida de almacenamiento prolongada que comprende ciclodextrina y medicamentos y promedicamentos que se descomponen en componentes insolubles en agua.
GB9713149D0 (en) 1997-06-21 1997-08-27 Pfizer Ltd Pharmaceutical formulations
TR200001199T2 (tr) 1997-11-07 2000-08-21 Pharmacia & Upjohn Company Oksazolidinonların üretimi için işlem
HUP9701945A3 (en) 1997-11-10 2000-04-28 Hexal Ag Pharmaceutical composition for injection containing cyclodextrin and taxoids
AU1598399A (en) 1997-12-01 1999-06-16 Schering Corporation Injectable antifungal formulations
EE200100026A (et) 1998-07-14 2002-06-17 Pharmacia & Upjohn Company Oksasolidinoonid silmahaiguste raviks
AR020660A1 (es) 1998-09-30 2002-05-22 Alcon Lab Inc Composiciones antibioticas para el tratamiento de ojos, oidos y nariz
US6316020B1 (en) 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
CA2384717C (en) * 1999-09-13 2010-07-27 Insite Vision Incorporated Topical treatment for prevention of ocular infections
US6319020B1 (en) * 1999-12-10 2001-11-20 Sonic Innovations, Inc. Programming connector for hearing devices
PE20020044A1 (es) 2000-06-16 2002-01-30 Upjohn Co Tiazina oxazolidinona
AR031135A1 (es) * 2000-10-10 2003-09-10 Upjohn Co Composiciones de antibiotico topico para el tratamiento de infecciones oculares

Also Published As

Publication number Publication date
AR030470A1 (es) 2003-08-20
PE20020300A1 (es) 2002-05-10
US6989381B2 (en) 2006-01-24
WO2002015940A3 (en) 2003-02-20
JP2004506699A (ja) 2004-03-04
KR20030027047A (ko) 2003-04-03
AU8508701A (en) 2002-03-04
AU2001285087B2 (en) 2006-08-03
DK1311296T3 (da) 2006-04-18
PL365674A1 (en) 2005-01-10
DE60115910D1 (de) 2006-01-19
ATE312627T1 (de) 2005-12-15
NZ524158A (en) 2004-12-24
IL154423A0 (en) 2003-09-17
DE60115910T2 (de) 2006-08-17
NO20030787D0 (no) 2003-02-19
CA2419597A1 (en) 2002-02-28
CY1105464T1 (el) 2010-04-28
WO2002015940A2 (en) 2002-02-28
BR0113363A (pt) 2004-01-06
US20020068720A1 (en) 2002-06-06
ES2250461T3 (es) 2006-04-16
MXPA03001531A (es) 2003-06-24
EP1311296A2 (en) 2003-05-21
EP1311296B1 (en) 2005-12-14

Similar Documents

Publication Publication Date Title
EE200300145A (et) Asa- ja polüasanaftalenüülkarboksamiidid ja farmatseutiline kompositsioon
NO20023012L (no) Innretning for avlevering av medikament med antiprogestine egenskaper
EE200300207A (et) Heterotsüklüülalküülpiperidiini derivaadid, nendevalmistamismeetodid ja farmatseutiline kompositsioon
NO20033244D0 (no) Farmasöytisk sammensetning med redusert tendens for legemiddelkrystallisasjon
FI991485A0 (fi) Uusi farmaseuttinen koostumus
NO20015175D0 (no) Farmasöytisk sammensetning
EE200300151A (et) Ravimitena kasutatavad antikolinergikumid ning meetodid nende valmistamiseks
NO20025450L (no) Ny farmasöytisk sammensetning
EE200300237A (et) Difenüülasetidinooni derivaadid, nende kasutamine, ravim ja selle valmistamismeetod
EE200300238A (et) Difenüülasetidinooni derivaadid, nende kasutamine, ravim ja selle valmistamismeetod
EE200200357A (et) Ravimaine suurenenud kontsentratsioone andvad farmatseutilised kompositsioonid
DK1524266T3 (da) Farmaceutisk sammensætning
FR2804025B1 (fr) Compositions pharmaceutiques stabilisees
EE05104B1 (et) Asetidiini derivaadid, nende valmistamise meetodid ja farmatseutiline kompositsioon
MA26882A1 (fr) COMPOSITIONS PHARMACEUTIQUES D'INHIBITEURS ET GLYCOGèNE-PHOSPHORYLASE
EE200300134A (et) Uued tiadiasoolid ja oksadiasoolid ning nende kasutamine fosfodiesteraas-7 inhibiitoritena
EE200200393A (et) Glüburiidi ravimkoostis
PT1225898E (pt) Composicoes farmaceuticas contendo um farmaco antibiotico de fluoroquinolona e goma xantana
NO20030787D0 (no) Opplösningssammensetning av et antibiotisk oksazolidinonlegemiddel med forhöyet legemiddelinnhold
EE200200498A (et) Asendatud 3-fenüül-5-alkoksü-1,3,4-oksadiasol-2-oon, selle valmistamine ja kasutamine hormoontundlikku lipaasi pärssivas ravimis ning seda sisaldav suhkurtõve ravim
PT1210119E (pt) Composicoes farmaceuticas para administracao oral e topica
NO20032614D0 (no) Farmasöytisk sammensetning med forbedret absorbabilitet
NO20042272L (no) Farmasoytiske blandinger og fremgangsmater for administrering av EP2-reseptor selektive agonister
PL361518A1 (pl) Zastosowanie substancji oraz kompozycja farmaceutyczna
DE60024476D1 (de) Pedikulizide und veterinärmedizinische zusammensetzungen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application